Cholangiocarcinoma Market to Exhibit Substantial Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – AstraZeneca, Basilea, Taiho Oncology, Eisai, TransThera, Incyte, Roche
DelveInsight’s “Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cholangiocarcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Cholangiocarcinoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Cholangiocarcinoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cholangiocarcinoma: An Overview
Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of the biliary duct and histologic and biochemical features of cholangiocyte differentiation. The major function of the bile duct is to move a fluid called bile from the liver and gallbladder to the small intestine, where it helps digest the fats in food.
In most cases, there are no signs of bile duct cancer until it reaches the later stages, when symptoms can include: jaundice, unintentional weight loss, and abdominal pain. CCA happens due to mutations that turn on oncogenes or turn off tumor suppressor genes, however, the reason behind these mutations is unclear.
Cholangiocarcinoma Market Key Facts
-
The total Cholangiocarcinoma market size in the United States accounted for USD 237.3 million in 2021 which is expected to rise during the study period (2019–2032).
-
In EU-5, the total Cholangiocarcinoma market size was USD 326 million in 2021.
-
In Japan, the total Cholangiocarcinoma market size was USD 165.5 million in 2021.
-
In the year 2021, the total diagnosed incident cases of Cholangiocarcinoma were 46,466 in the 7MM.
-
According to DelveInsight, in the year 2021, the total number of diagnosed incident cases of Cholangiocarcinoma was 10,034 in the United States.
-
The highest number of total incident cases of Cholangiocarcinoma was observed in Italy among the EU5 countries, with 6,489 cases in 2021.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Cholangiocarcinoma pipeline therapies. It also thoroughly assesses the Cholangiocarcinoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Cholangiocarcinoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cholangiocarcinoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Cholangiocarcinoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Cholangiocarcinoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Cholangiocarcinoma Epidemiology, Segmented as –
-
Incident Cases of CCA in the 7MM [2019–2032]
-
Stage-specific Incident Cases of CCA in the 7MM [2019–2032]
-
Biomarker-specific Incident Cases of CCA in the 7MM [2019–2032]
-
Age-specific Incident Cases of CCA in the 7MM [2019–2032]
-
Type-specific Incident Cases of CCA in the 7MM [2019–2032]
Cholangiocarcinoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Cholangiocarcinoma market or expected to be launched during the study period. The analysis covers the Cholangiocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Cholangiocarcinoma drugs based on their sale and market share.
The report also covers the Cholangiocarcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Cholangiocarcinoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Cholangiocarcinoma Market Will Evolve and Grow by 2032 @
Cholangiocarcinoma Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Cholangiocarcinoma. Currently, ImmunoGen is leading the therapeutics market with its Cholangiocarcinoma drug candidates in the most advanced stage of clinical development.
Cholangiocarcinoma Companies Actively Working in the Therapeutics Market Include
-
AstraZeneca
-
Decalth Systems
-
Basilea Pharmaceutica
-
Taiho Oncology
-
Eisai Pharmaceuticals
-
TransThera Sciences
-
Incyte Corporation
-
Roche
-
Agios Pharmaceuticals
-
Servier Pharmaceuticals
And Many Others
Emerging and Marketed Cholangiocarcinoma Therapies Covered in the Report Include:
-
TAS-120: Taiho Oncology
-
Pembrolizumab: Merck Sharp & Dohme
-
E7090: Eisai
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cholangiocarcinoma Competitive Intelligence Analysis
4. Cholangiocarcinoma Market Overview at a Glance
5. Cholangiocarcinoma Disease Background and Overview
6. Cholangiocarcinoma Patient Journey
7. Cholangiocarcinoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Cholangiocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Cholangiocarcinoma Unmet Needs
10. Key Endpoints of Cholangiocarcinoma Treatment
11. Cholangiocarcinoma Marketed Therapies
12. Cholangiocarcinoma Emerging Drugs and Latest Therapeutic Advances
13. Cholangiocarcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Cholangiocarcinoma Market Outlook (In US, EU5, and Japan)
16. Cholangiocarcinoma Companies Active in the Market
17. Cholangiocarcinoma Access and Reimbursement Overview
18. KOL Views on the Cholangiocarcinoma Market
19. Cholangiocarcinoma Market Drivers
20. Cholangiocarcinoma Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Implantable Cardioverter Defibrillators (ICDs) Market
“Implantable Cardioverter Defibrillators (ICDs) Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Implantable Cardioverter Defibrillators market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Implantable Cardioverter Defibrillators Market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
 – DelveInsight | Key Companies – AstraZeneca, Basilea, Taiho Oncology, Eisai, TransThera, Incyte, Roche){kind=link}